YorkBridge Wealth Partners’s Neurocrine Biosciences NBIX Stock Holding History

YorkBridge Wealth Partners’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$309K	Sell	2,589 -765	-23%	-$89.6K	0.08%	184
2022 Q3	$356K	Sell	3,354 -215	-6%	-$21.8K	0.09%	160
2022 Q2	$348K	Sell	3,569 -554	-13%	-$51.1K	0.09%	170
2022 Q1	$387K	Buy	4,123 +1,411	+52%	+$120K	0.08%	184
2021 Q4	$231K	Sell	2,712 -1,019	-27%	-$93.7K	0.05%	261
2021 Q3	$358K	Buy	3,731 +679	+22%	+$64.1K	0.09%	193
2021 Q2	$297K	Buy	3,052 +148	+5%	+$14.2K	0.08%	208
2021 Q1	$282K	Buy	+2,904	New	+$305K	0.08%	210

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

YorkBridge Wealth Partners's NBIX Position: Q4 2022 in Review

YorkBridge Wealth Partners reduced its Neurocrine Biosciences (NBIX) stake by 23% in Q4 2022, selling an estimated $89.6K and leaving 2,589 shares worth $309K. The position accounts for 0.08% of the portfolio, ranked #184.

YorkBridge Wealth Partners first reported a position in NBIX in Q1 2021 and has held it in 8 quarters since. The position peaked at $387K in Q1 2022. 529 funds tracked by Wall St. Rank hold NBIX as of Q4 2022.

YorkBridge Wealth Partners held 2,589 shares of Neurocrine Biosciences worth $309K as of Q4 2022.
YorkBridge Wealth Partners sold 765 Neurocrine Biosciences shares in Q4 2022, an estimated $89.6K.
Neurocrine Biosciences made up 0.08% of YorkBridge Wealth Partners's portfolio in Q4 2022, its #184 holding.
YorkBridge Wealth Partners first reported a position in Neurocrine Biosciences in Q1 2021 and has held it in 8 quarters since.
YorkBridge Wealth Partners's Neurocrine Biosciences position peaked at $387K in Q1 2022.
529 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2022.

Based on YorkBridge Wealth Partners's 13F filing for Q4 2022, filed 26 Jan 2023.